Evidence map›Paper›PMID 38423818›Full record

ArticleVaccine2024

Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.

Dana Meaney-Delman, Sarah Carroll, Kara Polen, Tara C Jatlaoui, Sarah Meyer, Sara Oliver, Julianne Gee, Tom Shimabukuro, Hilda Razzaghi, Laura Riley and 5 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Dana Meaney-DelmanDivision of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: vmo0@cdc.gov.
Sarah CarrollAmerican College of Obstetricians and Gynecologists, Washington, D.C, United States.
Kara PolenDivision of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Tara C JatlaouiNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Sarah MeyerNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Sara OliverNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Julianne GeeImmunization Safety Office, Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Tom ShimabukuroImmunization Safety Office, Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Hilda RazzaghiNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Laura RileyDepartment of Obstetrics and Gynecology, Weill Cornell School of Medicine, New York, NY, United States.
Romeo R GalangDivision of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Van TongDivision of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Suzanne GilboaDivision of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Sascha EllingtonNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Amanda CohnDivision of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Centers for Disease Control and Prevention · USAmerican Congress of Obstetricians and Gynecologists · USCornell University · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

As the worldwide COVID-19 pandemic unfolded, the clinical and public health community raced to understand SARS-CoV-2 infection and develop life-saving vaccines. Pregnant persons were disproportionately impacted, experiencing more severe illness and adverse pregnancy outcomes. And yet, when COVID-19 vaccines became available in late 2020, safety and efficacy data were not available to inform their use during pregnancy because pregnant persons were excluded from pre-authorization clinical trials. Concerns about vaccine safety during pregnancy and misinformation linking vaccination and infertility circulated widely, creating a lack of vaccine confidence. Many pregnant people initially chose not to get vaccinated, and while vaccination rates rose after safety and effectiveness data became available, COVID-19 vaccine acceptance was suboptimal and varied across racial and ethnic distribution of the pregnant population. The COVID-19 pandemic experience provided valuable insights that can inform current and future approaches to maternal vaccination against.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2VaccinationFemaleHumansImmunizationPandemicsPregnancyPregnancy Complications, InfectiousCOVID-19 VaccinesCOVID-19Maternal immunizationVaccine

Identifiers

PMID38423818
PMCPMC11349930
OpenAlexW4392301770

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.